Drugs / CSL760
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04638634 | Feb → Jun 2021 | COVID-19 | CSL Behring | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSL760 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04638634 ↗ |
| Modality | Protein / enzyme biologic | “human hyperimmune product of the purified gamma immunoglobulin (IgG) fraction of human plasma” NCT04638634 ↗ |
| Route | Intravenous | “Administered as an intravenous infusion” NCT04638634 ↗ |